Inflation Expected to Reach 6 in Q2 According to Top Economic Forecasters Wellness Industry Growth Sauna Health Benefits Highlighted in Fortune Report Nvidia Acknowledges Conceding China AI Chip Market to Huawei as Competition Intensifies US Payrolls Surge Past Expectations in April Yet Underlying Weakness Persists World Insurance Expands Midwest Footprint with Kansas Agency Acquisition London Tours Market Expands With HighSpeed and Landmark Experiences CGEN Q1 2026 Earnings EPS Misses Estimates but Stock Rises 728 on Pipeline Progress ITP Q3 2025 Earnings Narrowing Losses Amidst Challenging Market Conditions Applied Industrial Technologies AIT Q1 2026 Earnings Slight EPS Miss as Margins Face Pressure Presurance Holdings Q1 2024 Earnings Surprise Profit Beats Estimates But Shares Slide on Revenue Disclosures PSQH Q1 2026 Earnings Narrower Loss Beats Estimates as Stock Declines Nutrien Ltd NTR Q1 2026 Earnings EPS Misses Estimates by 473 Amid Challenging Market Conditions Creative Medical Technology Holdings CELZ Slips 13 as Stock Tests Key Support at 217 Dermata Therapeutics DRMA Stages Modest Recovery Support Holds Above 128 SCYNEXIS SCYX Falls 688 Key Support and Resistance Levels Under Scrutiny Inter Co Inc INTR Edges Higher as Shares Approach Resistance Level WT Offshore WTI Declines 542 as Stock Tests Key Support Zone GitHub Outages Threaten Microsofts AI Coding Edge as Competition Surges Fastly Inc FSLY Q1 2026 Earnings Solid EPS Beat Amid Revenue Gaps and Slight Stock Pullback PowerBank Corporation SUUN Surges 626 as Momentum Builds Above Key Support UVV Q1 2026 Earnings EPS Misses Estimates Sharply on Cost Headwinds PSNY Q4 2024 Earnings Massive EPS Miss as Losses Widen Dramatically CPIX Q1 2026 Earnings Net Loss Reported Shares Edge Higher RELL Q1 2026 Earnings EPS Surges Past Estimates Stock Reacts Negatively CarPartscom PRTS Q1 2026 Earnings EPS Beat Despite Challenging Environment CNTA Q1 2026 Earnings EPS Misses Estimates as PreRevenue Biotech Continues RD Investment RLAY Q1 2026 Earnings EPS Misses Consensus PreRevenue Biotech Maintains RD Focus